MEDICAL CANNABIS FOR THE GERMAN MARKET

Canify AG (formerly Bavaria Weed GmbH) is one of the first pharmaceutical companies with a manufacturing licence for the unlimited importation, packaging and market release of raw materials of cannabis in the European Union. Due to the in-house production, the company is able to purchase raw materials of cannabis from approved manufacturers in large quantities, to store them almost indefinitely, and package it as an active ingredient and/or medicine and market it in Europe with their own label or as a third-label product. The company distributes its products to European pharmaceutical wholesalers as well as directly to pharmacies.

Since March 2017, the sale of cannabis for medical purposes has been legal in Germany, and since the (partial) legalization in April 2024, it is no longer subject to the Narcotics Act. Medical cannabis is now available in German (online) pharmacies with a prescription. An increasing number of patients are switching from conventional medications to alternative medical cannabis. Especially in the field of pain management, several studies show that medical cannabis can improve patients’ quality of life. There is also evidence of its effectiveness for many other indications.

The German and European markets offer extremely high growth potential for Canify, as certified production in Germany allows for the import, storage, and demand-based processing of cannabis raw materials in correspondingly large quantities. Canify’s approach to sales and distribution is to make the cannabis business (Canna-Biz) as simple and convenient as possible for pharmacies and wholesalers. In addition, the pharmaceutical company offers customized manufacturing and market access solutions for third-party collaborators and sets standards in terms of quality, production capacity, and delivery times.